Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 10/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 10/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 10/20 | 1.00 |
| ▸ | PDE5A | O76074 | 3/20 | 1.00 |
| ▸ | PDE1A | P54750 | 3/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 3/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 3/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.66 |
| ▸ | YTHDC1 | Q96MU7 | 7/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798952 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3141400 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3141383 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL9738428 | 0.87 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3146230 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3133509 | 0.86 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL1321678 | 0.86 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL27993590 | 0.85 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL4460149 | 0.85 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3133797 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2015-03-05 | — | — | US | claimed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | claimed |
| EP-2834219-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | Almirall S.A. (ES) | 2015-02-11 | — | — | EP | claimed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | claimed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| WO-2013149959-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | claimed |
| EP-2647627-A1 | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | claimed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | claimed |
| EP-2121615-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | claimed |
| US-20090221613-A1 | Use of Adenine-Derived Compounds for the Treatment of Lupus | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS). (FR) | 2009-09-03 | — | — | US | claimed |
| EP-1996200-A1 | USE OF ADENINE-DERIVED COMPOUNDS FOR THE TREATMENT OF LUPUS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-12-03 | — | — | EP | claimed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| WO-2007101850-A1 | USE OF ADENINE-DERIVED COMPOUNDS FOR THE TREATMENT OF LUPUS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-09-13 | — | — | WO | claimed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | claimed |
| CN-1501927-A | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | 记忆药物公司 | 2004-06-02 | — | — | CN | claimed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | claimed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | PDE4A 1/4885PDE4B 5/4885PDE4C 8/4885 |
| US-20090221613-A1 | Use of Adenine-Derived Compounds for the Treatment of Lupus | SSB, PNP, NAMPT | PDE4A 546/4885PDE4B 418/4885PDE4C 391/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 367/4885PDE4B 274/4885PDE4C 462/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | PDE4A 1/4885PDE4B 5/4885PDE4C 8/4885 |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | SULT2A1, SULT1E1, SULT1A1 | PDE4A 4246/4885PDE4B 4063/4885PDE4C 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.